SPC537
Donanemab
Status:
UmsóknApplication date:
16.1.2026Application published:
11.2.2026
Medicine name:
KisunlaMedicine for children:
No
Timeline
Today
16.1.2026Application
11.2.2026Publication
Marketing license
Foreign authorization number:
EU/1/25/1926Date:
24.9.2025
Owner
Name:
Eli Lilly and CompanyAddress:
Lilly Corporate Center, Indianapolis US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2603523